SCHEMBL3016034

SCHEMBL3016034

Cc1cccc(Cc2csc(N3CCN(S(=O)(=O)c4c(F)cccc4F)CC3)n2)c1C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 8/20 0.45
PKLR P30613 5/20 0.45
ALDH1A1 P00352 4/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MEN1 O00255 4/20 0.42
LMNA P02545 4/20 0.42
KMT2A Q03164 4/20 0.42
MAPK1 P28482 3/20 0.42
MAPT P10636 3/20 0.41
AR P10275 1/20 0.41
USP2 O75604 1/20 0.41
RECQL P46063 1/20 0.41
HSD17B10 Q99714 1/20 0.41
TSHR P16473 3/20 0.40
HTT P42858 2/20 0.40
POLB P06746 1/20 0.40
GAA P10253 1/20 0.40
THRB P10828 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3001237 0.93 PKM (0.46) PKMPKLRALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL3013318 0.92 ALDH1A1 (0.42) ALDH1A1SMN1; SMN2L3MBTL1MEN1LMNA
SCHEMBL2997910 0.89 MEN1 (0.44) ALDH1A1SMN1; SMN2L3MBTL1MEN1LMNA
SCHEMBL3012895 0.89 PKM (0.48) PKMPKLRALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL3009137 0.88 KMT2A (0.42) PKMALDH1A1SMN1; SMN2L3MBTL1MEN1
SCHEMBL3019967 0.87 ALDH1A1 (0.59) PKMALDH1A1SMN1; SMN2L3MBTL1MEN1
SCHEMBL3003300 0.87 MAPT (0.38) PKMPKLRALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL3013890 0.87 PKM (0.43) PKMPKLRALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL3013261 0.86 ALDH1A1 (0.47) PKMPKLRALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL3013569 0.86 MAPT (0.47) PKMALDH1A1SMN1; SMN2L3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA PKM 1047/4885PKLR 2799/4885ALDH1A1 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.